Rybelsus

Caloric Restriction, at least one weight-related comorbid condition, Obesity + 6 more
Treatment
6 FDA approvals
20 Active Studies for Rybelsus

What is Rybelsus

SemaglutideThe Generic name of this drug
Treatment SummarySemaglutide is a medication used to treat type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) analogs. It was approved by the FDA in 2017 and can be injected once a week or taken as a tablet once a day. Semaglutide activates the GLP-1 receptor, which stimulates insulin secretion and lowers blood glucose levels. It has been shown to reduce HbA1c levels and body weight in people with type 2 diabetes. In 2021, it was also approved for chronic weight management in adults with general obesity or overweight.
Ozempicis the brand name
image of different drug pills on a surface
Rybelsus Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ozempic
Semaglutide
2017
19

Approved as Treatment by the FDA

Semaglutide, commonly known as Ozempic, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Cardiovascular Events .
Type 2 Diabetes Mellitus
Cardiovascular Events
Type 2 Diabetes
Cardiovascular Diseases
Physical Activity
Used in combination with other therapies
Diet
Used in combination with other therapies

Effectiveness

How Rybelsus Affects PatientsSemaglutide helps reduce levels of sugar in the blood, lower blood pressure, and cause weight loss. It does this by increasing insulin production and decreasing the amount of the hormone glucagon, which is usually linked to higher blood sugar levels. Semaglutide also decreases the amount of bad cholesterol and triglycerides in the body. However, it can cause medullary thyroid cell carcinoma in rodents, so those with a family history should not take this drug. It can also lead to pancreatitis, dehydration, and slower digestion, so patients should make sure to stay hydrated and be aware of the effects of other drugs
How Rybelsus works in the bodySemaglutide helps to control blood sugar by stimulating the pancreas to produce insulin and reducing the amount of glucagon, a hormone that raises blood sugar. It binds to the GLP-1 receptor and triggers other effects that help lower blood sugar. It also helps reduce the progression of atherosclerosis and can lead to weight loss by decreasing appetite and cravings.

When to interrupt dosage

The quantity of Rybelsus is contingent upon the determined condition, including Type 2 Diabetes, at least one weight-related comorbidity and reduced-calorie diet. The extent of dosage is subject to the mode of delivery (e.g. Solution - Subcutaneous or Subcutaneous) as noted in the table below.
Condition
Dosage
Administration
Obesity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Physical Activity
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Type 2 Diabetes
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Diet
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Chronic Weight Management therapy
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Diseases
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Caloric Restriction
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
at least one weight-related comorbid condition
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension
Cardiovascular Events
, 1.34 mg/mL, 1.0 mg, 3.0 mg, 7.0 mg, 14.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/pump actuation, 5.0 mg/mL, 2.5 mg/mL, 24.0 mg/mL, 10.0 mg/mL, 17.0 mg/mL, 2.68 mg/mL, 2.4 mg, 1.7 mg, 20.0 mg/mL
Solution, Solution - Subcutaneous, , Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Tablet - Oral, Tablet, Oral, Injection, powder, lyophilized, for suspension - Oral, Injection, powder, lyophilized, for suspension

Warnings

Rybelsus Contraindications
Condition
Risk Level
Notes
Multiple Endocrine Neoplasia
Do Not Combine
Thyroid Neoplasms
Do Not Combine
Medullary carcinoma of thyroid
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Semaglutide may interact with Pulse Frequency
There are 20 known major drug interactions with Rybelsus.
Common Rybelsus Drug Interactions
Drug Name
Risk Level
Description
Acetohexamide
Moderate
Semaglutide may increase the hypoglycemic activities of Acetohexamide.
Carbutamide
Moderate
Semaglutide may increase the hypoglycemic activities of Carbutamide.
Chlorpropamide
Moderate
Semaglutide may increase the hypoglycemic activities of Chlorpropamide.
Englitazone
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Englitazone.
Fluconazole
Moderate
The risk or severity of hypoglycemia can be increased when Semaglutide is combined with Fluconazole.
Rybelsus Toxicity & Overdose RiskPeople who take too much semaglutide (more than 4 mg in one dose) may experience nausea, although full recovery is expected. Patients should be monitored and given supportive care as needed, as the drug can remain in the body for up to one week. There is no specific antidote for an overdose of semaglutide.
image of a doctor in a lab doing drug, clinical research

Rybelsus Novel Uses: Which Conditions Have a Clinical Trial Featuring Rybelsus?

196 active studies are currently investigating the potential of Rybelsus to address Diseases and weight-related comorbidities, in individuals with a Body Mass Index >27 kg/m2.
Condition
Clinical Trials
Trial Phases
Physical Activity
28 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1
Cardiovascular Diseases
0 Actively Recruiting
Type 2 Diabetes
172 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Cardiovascular Events
4 Actively Recruiting
Not Applicable
at least one weight-related comorbid condition
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Caloric Restriction
0 Actively Recruiting
Obesity
0 Actively Recruiting
Diet
5 Actively Recruiting
Not Applicable, Phase 1

Rybelsus Reviews: What are patients saying about Rybelsus?

5Patient Review
7/4/2022
Rybelsus for Type 2 Diabetes Mellitus
I've been taking 7mg for almost a year now and have seen some great results like losing 20lbs, lower blood sugar, and A1c. I also haven't experienced any negative side effects, which is amazing.
5Patient Review
7/4/2022
Rybelsus for Type 2 Diabetes Mellitus
I've been taking 7mg of this medication for nearly a year and have seen some great results, like losing 20lbs and bringing my blood sugar down. My A1C is also down with no negative side effects!
5Patient Review
8/29/2022
Rybelsus for Type 2 Diabetes Mellitus
I gradually increased my dosage over the course of three months and saw significant results. I lost 17 pounds without any negative side effects.
4.7Patient Review
11/2/2022
Rybelsus for Type 2 Diabetes Mellitus
At first, this medication made me feel nauseous and I had no appetite. However, once I got used to it, it was much better. I also discovered that if you hold the pill in your mouth for too long, it has a really bitter taste (yuck). So my advice is to put the pill near the back of your tongue and quickly drink some water. In just three months, my A1C went from 8.2 to 6.4, and I lost six pounds in addition to taking 1000 mg Metformin.
4.3Patient Review
9/13/2021
Rybelsus for Type 2 Diabetes Mellitus
I've had a lot of trouble in the past taking diabetic medication, but Rybellsus has been different. No upset stomach or urinary problems. Blood sugar is better controlled and I'm hoping to be moved up to 14mg soon.
4.3Patient Review
7/18/2022
Rybelsus for Type 2 Diabetes Mellitus
I saw a significant drop in my blood sugar levels after taking this medication.
3.7Patient Review
4/4/2022
Rybelsus for Type 2 Diabetes Mellitus
I've been taking rybelsus for three weeks now and have had no major issues. I will be upping my dosage to seven milligrams next week, and so far everything has been going well. The only thing I experienced at the beginning was slight lightheadedness, but that passed quickly.
3Patient Review
5/11/2022
Rybelsus for Type 2 Diabetes Mellitus
I was using 3mg for a month and experiencing symptoms like bladderfulness and nausea. I increased the dosage to 7mg for the last 15 days, but the side effects are the same. The only difference is that my sugar levels have come down.
2.7Patient Review
10/23/2021
Rybelsus for Type 2 Diabetes Mellitus
I had some normal side effects at first, but they got worse after a few days instead of better. I stopped taking the pill after 15 days because I couldn't handle the side effects anymore.
2.7Patient Review
4/18/2022
Rybelsus for Type 2 Diabetes Mellitus
The smaller strength pills had no real effect on appetite. The largest dose caused extreme nausea and diarrhea. Could not eat to take nailing because I felt so sick. The should be other strengths
1.7Patient Review
7/12/2022
Rybelsus for Type 2 Diabetes Mellitus
I started taking Rybelsus last year and again this year. No effect on weight loss, no effect on my blood sugar. I had stomach pain, heartbeat, constipation and lower back pain. After every 6 month I had problem with vomiting. I think Rybelsus give me Acute gallbladder disease. Every time I stop taking it, after a few days all the side effect was gone.I will never take it again. The biggest effect of Rybelsus was on my wallet
1.7Patient Review
9/1/2022
Rybelsus for Type 2 Diabetes Mellitus
I have been taking Rybelsus for a year and a half at the 7 mg dosage. Unfortunately, it has made my life quite miserable. I experience terrible bloating, stomach pain, and gas on a regular basis. I've even lost around 40 pounds because of how little I can eat while on this medication. Additionally, it started giving me heart palpitations and is no longer effectively controlling my blood sugar levels - even when I consume very few carbs. So, I'm planning to speak with my doctor soon about finding an alternative treatment option.
1.7Patient Review
6/7/2022
Rybelsus for Type 2 Diabetes Mellitus
This medication made me so sick after only the second dose. I had diarrhea, vomiting and nausea so bad that I couldn't move. I discontinued it right away. Of course you will lose weight if you can't keep food down.
1.7Patient Review
6/22/2022
Rybelsus for Type 2 Diabetes Mellitus
My A1C readings did not budge after using this treatment, and if anything, my average daily glucose readings went up by over 150 points.
1.3Patient Review
9/24/2022
Rybelsus for Type 2 Diabetes Mellitus
I'm on day four of the treatment, and I've been feeling a strong metallic taste in my mouth. Additionally, it feels like I was punched in my right kidney. If these symptoms don't improve by day seven, I'll be stopping the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rybelsus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does the drug Rybelsus do?

"Rybelsus is a hormone that helps to lower blood sugar levels by mimicking the effects of the protein GLP-1, which is found naturally in the body and helps to control blood sugar levels."

Answered by AI

Is Rybelsus the same as metformin?

"A major difference between Rybelsus and metformin is that Rybelsus is a newer brand-name medication that isn't available as a generic yet, while metformin is available as a lower-cost generic."

Answered by AI

Is Rybelsus a weight loss pill?

"If you are an adult with type 2 diabetes, RYBELSUS® may be a medication option for you. This medication is intended to be used in conjunction with diet and exercise to improve blood sugar levels and A1C. Although weight loss is not a primary goal of this medication, some patients may experience weight loss as a side effect."

Answered by AI

How effective is Rybelsus for weight loss?

"Although Rybelsus is not explicitly marketed as a weight loss drug, many people report losing weight while taking it. On average, people lost 5 pounds (2.3 kg) while taking the 7 mg dose, and 8.1 pounds (3.7 kg) while taking the 14 mg dose. One of the ways Rybelsus is believed to work is by helping to make users feel full after a meal."

Answered by AI

Clinical Trials for Rybelsus

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA
The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.
Recruiting
Has No Placebo
University of California, Los AngelesLauren E Wisk, PhD
Image of Medpace Clinical Pharmaology Unit in Cincinnati, United States.

PATAS for Type 2 Diabetes

18 - 55
All Sexes
Cincinnati, OH
The primary objective of Part 1 of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of Part 1 of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects. The primary objectives of Part 2 of this study are to evaluate the safety and tolerability of 4 weekly SC doses of PATAS in subjects with T2D; and to determine the PK and pharmacodynamics (PD) of 4 weekly SC doses of PATAS in subjects with T2D. The secondary objectives of Part 2 of this study are to evaluate the potential effect of multiple SC doses of PATAS on markers of glycemic control, as measured by glucose levels, insulin levels, and other metabolomic biomarkers; and to characterize the adverse event (AE) profiles of the various dose levels of PATAS.
Phase 1
Waitlist Available
Medpace Clinical Pharmaology UnitVincent Marion, Ph.D.AdipoPharma LLC
Have you considered Rybelsus clinical trials? We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.Go to Trials
Image of University of British Columbia - Okanagan in Kelowna, Canada.

Estrogen and Testosterone for Gender Differences in Physiology

18 - 40
All Sexes
Kelowna, Canada
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.
Waitlist Available
Has No Placebo
University of British Columbia - OkanaganPhilip Ainslie, PhD
Have you considered Rybelsus clinical trials? We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.Go to Trials
Image of Exercise Metabolism and Inflammation Laboratory in Okanagan, Canada.

Aerobic Exercise with Blood Flow Restriction for Type 2 Diabetes

19 - 64
All Sexes
Okanagan, Canada
The goal of this trial is to learn if blood flow restriction training with treadmill walking is possible for individuals living with type 2 diabetes. It will also learn about how the blood flow restriction with treadmill walking could improve health. The main questions it aims to answer are: Is 6 weeks of treadmill walking with blood flow restriction reasonable for people with type 2 diabetes to perform? Does treadmill walking with blood flow restriction training help manage type 2 diabetes better than just treadmill walking? Researchers will compare treadmill walking with blood flow restriction to treadmill walking without blood flow restriction to see if blood flow restriction works to manage type 2 diabetes based on fitness and blood sugar levels. Participants will: Perform treadmill walking with or without blood flow restriction for 96 minutes a week for 6 weeks. Visit the lab before and after the exercise for tests and questionnaires.
Waitlist Available
Has No Placebo
Exercise Metabolism and Inflammation Laboratory (+2 Sites)Martin Senechal, PhD
Image of Jefferson Health New Jersey in Sewell, United States.

Continuous vs Finger-stick Glucose Monitoring for Type 2 Diabetes in Pregnancy

18+
Female
Sewell, NJ
The purpose of this study is to compare patient adherence to blood sugar monitoring during pregnancy using two different measurement methods in pregnancies complicated by pregestational type 2 diabetes (T2DM). Pregnant patients with T2DM are at risk of having larger babies, babies with low sugar levels in the first 24 hours of life, higher rates of cesarean delivery, stillbirth (death of baby inside the womb), and hypertensive or high blood pressure disorders of pregnancy, such as preeclampsia. Prior studies have shown that treating high blood sugars in pregnancy with medications can reduce these risks. To determine the amount of medication needed, recording of blood sugar levels is necessary. This trial aims to determine whether continuous blood sugar monitors have improved patient recording of blood sugar levels over finger stick blood sugar measurements. Patients involved in the study will be assigned to either: 1. Fingerstick glucose monitoring (FSG) 2. Continuous glucose monitoring (CGM) Patients will be randomize in a 1:1 ratio. FSG Group: blood sugar is tested four times daily - once fasting and two hours after every meal (post-prandial). Blood will be tested using a glucometer, and values will be recorded in a blood sugar log from the time of enrollment to the time of delivery. CGM Group: A CGM sensor will be placed on the patient's arm for blood sugar collection every 3-5 minutes. This data is sent to a phone application from the time of enrollment to the time of delivery. These sensors will need to be replaced every 14 days. Percent adherence will be recorded from the time you were randomized to a study group until delivery.
Recruiting
Has No Placebo
Jefferson Health New Jersey (+1 Sites)
Image of McMaster University in Hamilton, Canada.

Health Coaching for Type 2 Diabetes and Mental Health

18+
All Sexes
Hamilton, Canada
Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health. The purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.
Waitlist Available
Has No Placebo
McMaster UniversityCarly Whitmore, RN PhD
Have you considered Rybelsus clinical trials? We made a collection of clinical trials featuring Rybelsus, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security